Navigation Links
Biovista Inc. and FDA to Collaborate on a Medication Safety Initiative
Date:1/12/2010

CHARLOTTESVILLE, Virginia, January 12 /PRNewswire/ -- Biovista Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed its technology platform to help analyze, identify, and better understand the way certain drugs can cause harmful side effects.

The FDA's Office of Clinical Pharmacology, within the Center for Drug Evaluation and Research (CDER), will test the use of Biovista's Adverse Event Analysis (AEA) technology and work closely with Biovista scientists to carefully study the serious side effects of several drugs or classes of drugs, identified by FDA, to help promote safer use of these medications. The goal of the collaboration is to explore the possibility of being able to predict which patients may be most likely to experience adverse reactions to these medications so that healthcare providers can better protect their safety.

"We look forward to working with Biovista and using its technology platform which may help reduce risks associated with using certain medications and help improve how healthcare providers go about selecting the drugs they prescribe for their patients," said Lawrence J. Lesko, Ph.D., Director of the Office of Clinical Pharmacology at CDER. "This license is an example of how FDA hopes to work with leading-edge technologies and collaborators to meet the goals of the agency's Safe Use Initiative."

"We are very pleased to collaborate with FDA in the analysis of drug side effects, using our AEA technology. CDER's Office of Clinical Pharmacology has a track record of innovation. We believe FDA's new Safe Use Initiative is a natural fit for our unique AEA technology, and we look forward to working closely with FDA and potentially helping to improve the safe use of drug products," said Aris Persidis, Ph.D., President of Biovista Inc.

About Biovista's Adverse Event Analysis technology

Biovista's AEA technology forms part of the company's Clinical Outcomes Search Space (COSS(tm)) platform that focuses on mechanism of action-based correlations between drugs, disease efficacy and adverse events. The AEA technology cross-correlates over 8,000 diseases and 12,000 adverse events known to medicine against any target, drug or combination. This enables researchers to link pre-clinical experimental data directly with potential clinical outcomes, and to explore the possible risks of adverse events from a mechanistic perspective. It also helps researchers explain adverse events after these occur, in cases where these events were unexpected or not monitored for during trials, and to differentiate the causes of adverse events among a drug or the underlying disease.

About the Safe Use Initiative

The goal of FDA's Safe Use Initiative is to reduce preventable harm by identifying specific, preventable medication risks and developing, implementing and evaluating cross-sector interventions with partners who are committed to safe medication use.

    For more information, please contact:

    Dr. Aris Persidis
    Biovista, Inc.
    arisp@biovista.com
    +1-434-242-6514

SOURCE Biovista Inc.


'/>"/>
SOURCE Biovista Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biovista Inc. Named Top Innovator in Life Sciences
2. SIRO Clinpharm Collaborates with Mediscis, Broadens Early Phase Drug Development Expertise
3. The ZigBee Alliance and Continua Health Alliance Collaborate to Expand Telehealth Capabilities
4. Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
5. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
7. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
8. febit and TGen Collaborate to Study New DNA Capture Method
9. Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic
10. GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer Researchers
11. The Leukemia & Lymphoma Society and Memgen Collaborate on CLL Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
Breaking Medicine Technology:
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):